CELLECTAR BIOSCIENCES INC (CLRB) Fundamental Analysis & Valuation

NASDAQ:CLRB • US15117F8804

2.76 USD
-0.01 (-0.36%)
Last: Mar 6, 2026, 08:08 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This CLRB fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

2

Taking everything into account, CLRB scores 2 out of 10 in our fundamental rating. CLRB was compared to 519 industry peers in the Biotechnology industry. CLRB scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. CLRB does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

0

1. CLRB Profitability Analysis

1.1 Basic Checks

  • In the past year CLRB has reported negative net income.
  • CLRB had a negative operating cash flow in the past year.
  • In the past 5 years CLRB always reported negative net income.
  • CLRB had a negative operating cash flow in each of the past 5 years.
CLRB Yearly Net Income VS EBIT VS OCF VS FCFCLRB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M -40M -50M

1.2 Ratios

  • CLRB has a worse Return On Assets (-128.91%) than 80.96% of its industry peers.
  • With a Return On Equity value of -201.04%, CLRB is not doing good in the industry: 68.27% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -128.91%
ROE -201.04%
ROIC N/A
ROA(3y)-220.55%
ROA(5y)-150.45%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CLRB Yearly ROA, ROE, ROICCLRB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1K 2K 3K

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for CLRB so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CLRB Yearly Profit, Operating, Gross MarginsCLRB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. CLRB Health Analysis

2.1 Basic Checks

  • CLRB has more shares outstanding than it did 1 year ago.
  • The number of shares outstanding for CLRB has been increased compared to 5 years ago.
  • There is no outstanding debt for CLRB. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
CLRB Yearly Shares OutstandingCLRB Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 500K 1M 1.5M
CLRB Yearly Total Debt VS Total AssetsCLRB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

2.2 Solvency

  • CLRB has an Altman-Z score of -30.03. This is a bad value and indicates that CLRB is not financially healthy and even has some risk of bankruptcy.
  • The Altman-Z score of CLRB (-30.03) is worse than 87.31% of its industry peers.
  • CLRB has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -30.03
ROIC/WACCN/A
WACCN/A
CLRB Yearly LT Debt VS Equity VS FCFCLRB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M -40M

2.3 Liquidity

  • A Current Ratio of 2.77 indicates that CLRB has no problem at all paying its short term obligations.
  • The Current ratio of CLRB (2.77) is worse than 66.73% of its industry peers.
  • A Quick Ratio of 2.77 indicates that CLRB has no problem at all paying its short term obligations.
  • With a Quick ratio value of 2.77, CLRB is not doing good in the industry: 64.62% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 2.77
Quick Ratio 2.77
CLRB Yearly Current Assets VS Current LiabilitesCLRB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. CLRB Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 79.78% over the past year.
EPS 1Y (TTM)79.78%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%88.25%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • CLRB is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 14.61% yearly.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y68%
EPS Next 2Y33.87%
EPS Next 3Y22.96%
EPS Next 5Y14.61%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
CLRB Yearly Revenue VS EstimatesCLRB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2027 2028 2029 2030 2031 2032 2033 50M 100M 150M 200M 250M
CLRB Yearly EPS VS EstimatesCLRB Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 -1K -2K -3K

More info and screens

Find the best growth stocksShow best growing peers

1

4. CLRB Valuation Analysis

4.1 Price/Earnings Ratio

  • CLRB reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CLRB. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CLRB Price Earnings VS Forward Price EarningsCLRB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CLRB Per share dataCLRB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 -4 -6 -8 -10

4.3 Compensation for Growth

  • A more expensive valuation may be justified as CLRB's earnings are expected to grow with 22.96% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y33.87%
EPS Next 3Y22.96%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. CLRB Dividend Analysis

5.1 Amount

  • CLRB does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

CLRB Fundamentals: All Metrics, Ratios and Statistics

CELLECTAR BIOSCIENCES INC

NASDAQ:CLRB (3/6/2026, 8:08:39 PM)

2.76

-0.01 (-0.36%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-13
Earnings (Next)03-11
Inst Owners7.01%
Inst Owner Change17.11%
Ins Owners0.58%
Ins Owner Change0%
Market Cap11.70M
Revenue(TTM)N/A
Net Income(TTM)-18.86M
Analysts80
Price Target47.94 (1636.96%)
Short Float %2.87%
Short Ratio1.5
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)30.04%
Min EPS beat(2)14.78%
Max EPS beat(2)45.31%
EPS beat(4)4
Avg EPS beat(4)39.84%
Min EPS beat(4)14.78%
Max EPS beat(4)83.31%
EPS beat(8)5
Avg EPS beat(8)26.48%
EPS beat(12)7
Avg EPS beat(12)17.37%
EPS beat(16)9
Avg EPS beat(16)12.83%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-44.05%
EPS NQ rev (1m)0%
EPS NQ rev (3m)6.15%
EPS NY rev (1m)0%
EPS NY rev (3m)2.57%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.25
P/tB 1.25
EV/EBITDA N/A
EPS(TTM)-10.8
EYN/A
EPS(NY)-7.67
Fwd EYN/A
FCF(TTM)-7.04
FCFYN/A
OCF(TTM)-7.02
OCFYN/A
SpS0
BVpS2.21
TBVpS2.21
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -128.91%
ROE -201.04%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-220.55%
ROA(5y)-150.45%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 25.63%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.77
Quick Ratio 2.77
Altman-Z -30.03
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)212.71%
Cap/Depr(5y)154.86%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)79.78%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%88.25%
EPS Next Y68%
EPS Next 2Y33.87%
EPS Next 3Y22.96%
EPS Next 5Y14.61%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y40.9%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y3.48%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y1.38%
OCF growth 3YN/A
OCF growth 5YN/A

CELLECTAR BIOSCIENCES INC / CLRB FAQ

Can you provide the ChartMill fundamental rating for CELLECTAR BIOSCIENCES INC?

ChartMill assigns a fundamental rating of 2 / 10 to CLRB.


What is the valuation status of CELLECTAR BIOSCIENCES INC (CLRB) stock?

ChartMill assigns a valuation rating of 1 / 10 to CELLECTAR BIOSCIENCES INC (CLRB). This can be considered as Overvalued.


Can you provide the profitability details for CELLECTAR BIOSCIENCES INC?

CELLECTAR BIOSCIENCES INC (CLRB) has a profitability rating of 0 / 10.


Can you provide the financial health for CLRB stock?

The financial health rating of CELLECTAR BIOSCIENCES INC (CLRB) is 5 / 10.